HK2 and lung cancer: Previous studies also have found that downregulating Hexokinases II (HK2)-mediated glycolysis by Deguelin or downregulating ATK-mediated glycolysis by miR-128 suppresses the progression of lung cancer [14, 15], suggesting that glycolysis suppression might be a strategy for drug-resistant LUAD treatment.